This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Nov 27, 2024
•
9 min read
Roche paying a pretty penny for Poseida's allogeneic cell therapy ambitions, Amgen's MariTide weight loss Ph2 data isn't enough for investors, Cradle Bio $73M Series B for AI-driven protein design, Roche’s anti-TIGIT mAb misses in lung cancer Ph3 + 26 more stories
Nov 26, 2024
Cassava's much-controversial Alzheimer's hopeful flunks in Ph3, Alnylam whips out the priority review voucher for cardiomyopathy asset, Adcendo's ADC hopes get $135M injection, AstraZeneca touts Truqap prostrate cancer subtype Ph3 win + 27 more stories
Nov 25, 2024
8 min read
BridgeBio's Attruby lands FDA approval, Roche's Vabysmo touts potentially lucrative (in Asia) Ph3b/4 data in polypoidal choroidal vasculopathy, Nabla Bio's coming for the AI-designed protein crown, ALS hopeful Seelos Therapeutics files for bankruptcy + 21 more stories
Nov 22, 2024
Novartis buys gene therapy's Kate Therapeutics for up to $1.1B, Enveda snags $130M Series C on AI-analyzed plant-derived molecules, Pharma ads might go bye-bye if RFK Jr. has his way, CBER's Peter Marks sees vaccine debates as not "a bad thing", Pyxis Oncology’s PYX-201 Ph1 data doesn't inspire investor confidence + 25 more stories
Nov 21, 2024
10 min read
Pfizer signs drug discovery partnerships with two Flagship portfolio companies, Samsung Biologics scores a bunch of European manufacturing deal, Novartis and Vyriad partner on in-vivo CAR-T generation, Sage Therapeutics' potentially fatal Ph2 blow, RFK Jr. wants to "blow...up" the FDA + 29 more stories
Nov 20, 2024
Dr. Oz to lead Medicare & Medicaid, “fail fast” biotech venture foundry Jupiter Bioventures launches with $70M, BeiGene (soon to BeOne Medicines) settles Brukinsa generic spat with MSN Pharmaceuticals, AstraZeneca’s Andexxa FDA adcom chances not looking good after “major safety findings” + 31 more stories
Nov 19, 2024
Intellia's rare heart disorder CRISPR therapy looks solid in Ph1, AstraZeneca exercises option for Quell Therapeutics cell therapy, Novartis & Ratio Therapeutics' $745M radiotherapy development partnership, Neurogene stock drops even further as one Rett syndrome gene therapy recipient now in “critical condition” + 29 more stories
Nov 18, 2024
12 min read
Vaccine maker stocks dip on upcoming RFK Jr.-led HHS, Amgen showcases rare disease haul, Evotec stocks get boost from Halozyme takeover offer, Eli Lilly joins the 340B lawsuit party + 37 more biotech & pharma stories
Nov 15, 2024
RFK Jr. to the HHS, Merck joins the bispecific party with $588M, BeiGene wants a name change, and 31 more biotech/pharma stories
Nov 14, 2024
BioNTech buys bispecific partner Biotheus for $800M, PTC Therapeutics rare disease gene therapy Kebilidi land FDA approval, Adaptimmune touts positive Ph2 lete-cel data, Metsera $215M Series B to fuel obesity ambitions, UK’s NICE agrees to reassess Sanofi’s Sarclisa, Sanofi & Healx partner on finding indications to match a discontinued late stage asset, ICU Medical & Otsuka Pharmaceutical Factory partner on bolstering North American IV solution network, Syros Pharmaceuticals myelodysplastic syndrome drug combo misses Ph3 endpoint, Marinus Pharmaceuticals cuts 45% of staff, a hidden spreadsheet tab cost Amgen $12B in market cap, FDA continues struggling with retaining drug manufacturing site inspectors
Nov 13, 2024
Trace Neuroscience launches with $101M and ALS therapy goals, Apollo Therapeutics buys ex-China rights to Sunshine Lake Pharma diabetes clinical asset, Alentis Therapeutics $181.4M Series D to accelerate ADC pipeline, AstraZeneca plans $3.5B & 1000+ jobs investment in the US, Roche & Flare Therapeutics collaborate on cancer drug discovery, Intercept Pharmaceutical’s full Ocaliva approval rejected by FDA, Neurogene stock collapses after Rett syndrome gene therapy serious adverse event, Bayer’s CEO calls Q3 earnings “not pretty”, Pfizer considers hospital drugs business divestiture as activist investor pressure continues, AstraZeneca’s CEO says they didn’t “lose oversight” regarding Chinese executive criminal investigations
Nov 12, 2024
AbbVie may be feeling buyer's remorse as $8.9B Cereval buy delivers two Ph2 misses, IDEAYA Biosciences exercises licensing option for Biocytogen ADC asset, Novavax flu, COVID-19 vaccines clinical holds lifted, Novelty Nobility $24.8M Series C for solid tumour ADCs, Evotec becomes alleged acquisition target of PE firm Triton Partners, Doctors Without Borders pushes insulin pen makers to offer $1 pens in low and middle-income countries, 23andMe cuts 40% of their staff, Cigna denies considering Humana acquisition, Rapt Therapeutics drops autoimmune small molecule after negative FDA feedback
